[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Samuels SE, Knowles AL, Tilignac T, Debiton E, Madelmont JC, Attaix D: Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice. Cancer Res; 2000 Sep 1;60(17):4968-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice.
  • The impact of cancer cachexia and chemotherapy on small intestinal protein metabolism and its subsequent recovery was investigated.
  • Cancer cachexia was induced in mice with colon 26 adenocarcinoma, which is a small and slow-growing tumor characteristic of the human condition, and can be cured with 100% efficacy using an experimental nitrosourea, cystemustine (C6H12ClN3O4S).
  • Both healthy mice and tumor-bearing mice were given a single i.p. injection of cystemustine (20 mg/kg) 3 days after the onset of cachexia.
  • Cancer cachexia led to a reduced in vivo rate of protein synthesis in the small intestine relative to healthy mice (-13 to -34%; P < 0.05), resulting in a 25% loss of protein mass (P < 0.05), and decreased villus width and crypt depth (P < 0.05).
  • In treated mice, acute cytotoxicity of chemotherapy did not promote further wasting of small intestinal protein mass, nor did it result in further damage to intestinal morphology.
  • In contrast, mucosal damage and a 17% reduction in small intestinal protein mass (P < 0.05) were evident in healthy mice treated with cystemustine, suggesting that the effects of chemotherapy on the small intestine in a state of cancer cachexia are not additive, which was an unexpected finding.
  • Complete and rapid recovery of small intestinal protein mass in cured mice resulted from an increase in the rate of protein synthesis compared with healthy mice (23-34%; P < 0.05).
  • A major clinical goal should be to design methods to improve small intestinal protein metabolism before the initiation of chemotherapy.
  • [MeSH-major] Adenocarcinoma / complications. Antineoplastic Agents / toxicity. Cachexia / metabolism. Colonic Neoplasms / complications. Intestine, Small / metabolism. Nitrosourea Compounds / toxicity. Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10987314.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / Proteins; 0 / Ubiquitins; 79955-36-5 / N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


2. Sinha SC, Li LS, Miller GP, Dutta S, Rader C, Lerner RA: Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab. Proc Natl Acad Sci U S A; 2004 Mar 2;101(9):3095-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab.
  • Prodrugs of dynemicin analogs were synthesized, and their activation by aldolase antibody (Ab) 38C2 was evaluated by DNA-cleaving activity, as well as tumor cell growth inhibition.
  • Further, we provide evidence that the activated enediynes underwent covalent crosscoupling with the aldolase Ab, which appears to be a limiting factor of their tumor cell growth-inhibiting activity and should be of general interest in the field of enediyne chemotherapy.
  • These findings might open new avenues for defined conjugations of small molecule drugs to mAbs in general and aldolase Abs in particular.
  • [MeSH-major] Anthraquinones / chemical synthesis. Anthraquinones / therapeutic use. Antibiotics, Antineoplastic / chemistry. Antibodies, Catalytic / metabolism. Fructose-Bisphosphate Aldolase / immunology
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Colonic Neoplasms. Drug Design. Humans. Indicators and Reagents. Mass Spectrometry. Prodrugs / chemistry. Prodrugs / toxicity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1A):605-13 [10226606.001]
  • [Cites] Bioorg Med Chem Lett. 1999 Dec 20;9(24):3417-22 [10617083.001]
  • [Cites] Curr Opin Immunol. 1999 Oct;11(5):579-83 [10508703.001]
  • [Cites] Org Lett. 2000 Mar 23;2(6):811-3 [10754683.001]
  • [Cites] Org Lett. 1999 Nov 18;1(10):1623-6 [10836025.001]
  • [Cites] Chemistry. 2000 Aug 4;6(15):2772-4 [10985725.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7528-33 [11404472.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3314-24 [11705842.001]
  • [Cites] Chembiochem. 2001 Sep 3;2(9):656-65 [11828502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5396-400 [12702756.001]
  • [Cites] Science. 2003 Sep 12;301(5639):1537-41 [12970566.001]
  • [Cites] J Mol Biol. 2003 Sep 26;332(4):889-99 [12972259.001]
  • [Cites] Science. 1986 Dec 19;234(4783):1566-70 [3787261.001]
  • [Cites] Science. 1986 Dec 19;234(4783):1570-3 [3787262.001]
  • [Cites] Science. 1992 May 22;256(5060):1172-8 [1589797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5337-40 [8506382.001]
  • [Cites] Science. 1995 Dec 15;270(5243):1797-800 [8525368.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):799-803 [8570638.001]
  • [Cites] Science. 1997 Dec 19;278(5346):2085-92 [9405338.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14603-8 [9843936.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6925-30 [10359815.001]
  • (PMID = 14981258.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthraquinones; 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Catalytic; 0 / Indicators and Reagents; 0 / Prodrugs; EC 4.1.2.13 / Fructose-Bisphosphate Aldolase
  • [Other-IDs] NLM/ PMC365749
  •  go-up   go-down


3. Azevedo CR, Cezana L, Moraes ES, Begnami MD, Paiva Júnior TF, Dettino AL, Fanelli MF: Synchronous thyroid and colon metastases from epidermoid carcinoma of the lung: case report. Sao Paulo Med J; 2010 Dec;128(6):371-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous thyroid and colon metastases from epidermoid carcinoma of the lung: case report.
  • CONTEXT: Non-small cell lung cancer (NSCLC) progresses to distant metastases in most cases.
  • CASE REPORT: We describe a case of squamous cell carcinoma in the lungs, with metastases in the colon and thyroid, in a 66-year-old female patient.
  • The lesion was unresectable and chemotherapy was started.
  • After third-line chemotherapy, the patient progressed with acute obstructive abdomen due to a retroperitoneal mass.
  • Metastases to the thyroid and colon are rarely reported in cases of epidermoid carcinoma of the lungs.
  • Gastrointestinal involvement in pulmonary metastases may affect the stomach, small intestine and colon, and cases of bleeding and perforation have already been reported.
  • We did not find any previous reports in the literature, on lung cancer with metastases concomitantly in the colon and thyroid, in a single patient.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Colonic Neoplasms / secondary. Lung Neoplasms / pathology. Thyroid Neoplasms / secondary

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308162.001).
  • [ISSN] 1806-9460
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


Advertisement
4. Bradshaw TD, Matthews CS, Cookson J, Chew EH, Shah M, Bailey K, Monks A, Harris E, Westwell AD, Wells G, Laughton CA, Stevens MF: Elucidation of thioredoxin as a molecular target for antitumor quinols. Cancer Res; 2005 May 1;65(9):3911-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heteroaromatic quinols 4-(benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dienone (1) and 4-(1-benzenesulfonyl-1H-indol-2-yl)-4-hydroxycyclohexa-2,5-dienone (2) exhibit potent and selective antitumor activity against colon, renal, and breast carcinoma cell lines in vitro (GI50 < 500 nmol/L).
  • In vivo growth inhibition of renal, colon, and breast xenografts has been observed.
  • Profound G2-M cell cycle block accompanied down-regulation of cdk1 gene transcription was corroborated by decreased CDK1 protein expression following treatment of HCT 116 cells with growth inhibitory concentrations of 1 or 2.
  • Binding has been confirmed, via mass spectrometry, between reduced human thioredoxin and 1.
  • Results are consistent with a mechanism of action of novel antitumor quinols involving inhibition of the small redox protein thioredoxin.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Colonic Neoplasms / drug therapy. Cyclohexanones / pharmacology. Hydroquinones / pharmacology. Sulfones / pharmacology. Thiazoles / pharmacology. Thioredoxins / metabolism
  • [MeSH-minor] Amino Acid Sequence. Benzothiazoles. Blotting, Western. Cell Cycle / drug effects. Cell Growth Processes / drug effects. Cell Line, Tumor. Drug Screening Assays, Antitumor. Humans. Insulin / metabolism. Mass Spectrometry. Molecular Sequence Data. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867391.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(1-benzenesulfonyl-6-fluoro-1H-indol-2-yl)-4-hydroxycyclohexa-2,5-dienone; 0 / 4-(benzothiazol-2-yl)-4-hydroxy-2,5-cyclohexadien-1-one; 0 / Antineoplastic Agents; 0 / Benzothiazoles; 0 / Cyclohexanones; 0 / Hydroquinones; 0 / Insulin; 0 / Sulfones; 0 / Thiazoles; 52500-60-4 / Thioredoxins
  •  go-up   go-down


5. Di Carlo I, Li Destri G, Lombardo R, Puleo S: Totally implantable arterial device (TIAD): a questionable complication. Hepatogastroenterology; 2003 May-Jun;50(51):821-2
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After intrahepatic chemotherapy, during the nursing of the totally implantable arterial device, the patient developed a mass close to the duodenal loop that disappeared seven months later.
  • The spontaneous decrease of this mass suggests the hypothesis of a hematoma due to a rupture of a pseudoaneurysm of a small collateral artery.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Colonic Neoplasms / drug therapy. Duodenum / blood supply. Floxuridine / administration & dosage. Hematoma / etiology. Infusion Pumps, Implantable / adverse effects. Infusions, Intra-Arterial / instrumentation. Liver Neoplasms / secondary. Postoperative Complications / etiology. Stomach / blood supply
  • [MeSH-minor] Arteries / injuries. Catheters, Indwelling / adverse effects. Chemotherapy, Adjuvant. Combined Modality Therapy. Follow-Up Studies. Humans. Remission, Spontaneous. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12828093.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 039LU44I5M / Floxuridine
  •  go-up   go-down


6. Müller J, Sidler D, Nachbur U, Wastling J, Brunner T, Hemphill A: Thiazolides inhibit growth and induce glutathione-S-transferase Pi (GSTP1)-dependent cell death in human colon cancer cells. Int J Cancer; 2008 Oct 15;123(8):1797-806
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thiazolides inhibit growth and induce glutathione-S-transferase Pi (GSTP1)-dependent cell death in human colon cancer cells.
  • Thiazolides are a novel class of broad-spectrum anti-infective drugs with promising in vitro and in vivo activities against intracellular and extracellular protozoan parasites.
  • Here we report that NTZ and the bromo-thiazolide RM4819, but not the carboxy-thiazolide RM4825, inhibited proliferation of the colon cancer cell line Caco2 and nontransformed human foreskin fibroblasts (HFF) at or below concentrations the compounds normally exhibit anti-parasitic activity.
  • Using affinity chromatography and mass spectrometry glutathione-S-transferase P1 (GSTP1) from the GST class Pi was identified as a major thiazolide-binding protein.
  • GSTP1 expression was more than 10 times higher in the thiazolide-sensitive Caco2 cells than in the less sensitive HFF cells.
  • Thiazolides may thus represent an interesting novel class of future cancer therapeutics.
  • [MeSH-major] Apoptosis / drug effects. Colonic Neoplasms / drug therapy. Colonic Neoplasms / enzymology. Glutathione S-Transferase pi / metabolism. Thiazoles / pharmacology
  • [MeSH-minor] Benzamides / pharmacology. Caco-2 Cells. Cell Growth Processes / drug effects. Doxorubicin / pharmacology. Flow Cytometry. Humans. Phosphatidylserines / metabolism. RNA, Small Interfering / genetics

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688861.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Phosphatidylserines; 0 / RM 4819; 0 / RNA, Small Interfering; 0 / Thiazoles; 80168379AG / Doxorubicin; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


7. Sharma MP, Bhatia V: Abdominal tuberculosis. Indian J Med Res; 2004 Oct;120(4):305-15
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peritoneal tuberculosis occurs in three forms : wet type with ascitis, dry type with adhesions, and fibrotic type with omental thickening and loculated ascites.
  • Ileocaecal and small bowel tuberculosis presents with a palpable mass in the right lower quadrant and/or complications of obstruction, perforation or malabsorption especially in the presence of stricture.
  • Rare clinical presentations include dysphagia, odynophagia and a mid oesophageal ulcer due to oesophageal tuberculosis, dyspepsia and gastric outlet obstruction due to gastroduodenal tuberculosis, lower abdominal pain and haematochezia due to colonic tuberculosis, and annular rectal stricture and multiple perianal fistulae due to rectal and anal involvement.
  • Useful modalities for investigating a suspected case include small bowel barium meal, barium enema, ultrasonography, computed tomographic scan and colonoscopy.
  • Management is with conventional antitubercular therapy for at least 6 months.
  • The recommended surgical procedures today are conservative and a period of preoperative drug therapy is controversial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15520484.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 57
  •  go-up   go-down


8. Chandra A, Lee L, Hossain F, Johal H: A rare case of isolated wound implantation of colorectal adenocarcinoma complicating an incisional hernia: case report and review of the literature. World J Surg Oncol; 2008;6:5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The reported case illustrates an instance of colonic adenocarcinoma presenting as an isolated tumour 3 1/2 years after open surgery.
  • CASE PRESENTATION: An 83 year old lady initially underwent an extended right open hemicolectomy for a mid-transverse colonic adenocarcinoma (T4N2M0).
  • After adjuvant chemotherapy, she was kept under regular surveillance.
  • At operation, a mass was found within the anterior abdominal wall complicating the incisional hernia.
  • This mass was widely resected and a laparotomy performed.
  • Histology confirmed an adenocarcinoma of colonic origin extending to one of the lateral margins.
  • CONCLUSION: The literature regarding recurrence of colonic tumours after open surgery reports low incidences of this occurring within abdominal incisions.
  • The literature indicates prognosis is poor, but the numbers are small and distinction is often not made between isolated recurrence and those with other sites of tumour recurrence.
  • [MeSH-minor] Abdominal Wall / pathology. Aged, 80 and over. Biopsy, Needle. Colectomy / methods. Female. Follow-Up Studies. Humans. Immunohistochemistry. Incidental Findings. Laparotomy. Risk Assessment. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2005 Nov 1;92(2):124-9 [16231370.001]
  • [Cites] Br J Radiol. 2006 Jul;79(943):572-7 [16823061.001]
  • [Cites] Ann Surg. 2000 Aug;232(2):181-6 [10903594.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1172-7; discussion 1177 [12352231.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Br J Surg. 1977 Dec;64(12):872-5 [338091.001]
  • [Cites] Dis Colon Rectum. 1983 Sep;26(9):571-2 [6223795.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • [Cites] Lancet. 1994 Jul 2;344(8914):58 [7912321.001]
  • [Cites] Eur J Surg Oncol. 1995 Oct;21(5):568-70 [7589609.001]
  • [Cites] Dis Colon Rectum. 1996 Feb;39(2):200-7 [8620788.001]
  • [Cites] Surg Endosc. 1998 Aug;12(8):1039-42 [9685538.001]
  • [Cites] Dig Surg. 1998;15(2):124-34 [9845574.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):219-26 [10100791.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):29-37 [15642423.001]
  • [Cites] JSLS. 2005 Apr-Jun;9(2):184-8 [15984707.001]
  • (PMID = 18201386.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC2253526
  •  go-up   go-down


9. Primik MF, Göschl S, Jakupec MA, Roller A, Keppler BK, Arion VB: Structure-activity relationships of highly cytotoxic copper(II) complexes with modified indolo[3,2-c]quinoline ligands. Inorg Chem; 2010 Dec 6;49(23):11084-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The new ligands and copper(II) complexes were characterized by (1)H and (13)C NMR, IR and electronic absorption spectroscopy, ESI mass spectrometry, magnetic susceptibility measurements in solution at 298 K ([Cu(HL(1a))Cl(2)] and [Cu(HL(4b))Cl(2)]), and X-ray crystallography ([Cu(HL(3b))Cl(2)]·3DMF, [Cu(HL(4b))Cl(2)]·2.4DMF, HL(5b) and [Cu(HL(5b))Cl(2)]·0.5CH(3)OH).
  • All complexes were tested for cytotoxicity in the human cancer cell lines CH1 (ovarian carcinoma), A549 (non-small cell lung cancer), and SW480 (colon carcinoma).
  • Electron-releasing or electron-withdrawing substituents in position 8 of the indoloquinoline backbone do not exert any effect on cytotoxicity of copper(II) complexes, whereas copper(II) compounds with Schiff bases obtained from 2-acetylpyridine and indoloquinoline hydrazines are 10 to 50 times more cytotoxic than those with ligands prepared from 2-formylpyridine and indoloquinoline hydrazines.
  • [MeSH-minor] Carcinoma / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Cell Line, Tumor. Colonic Neoplasms / drug therapy. Crystallography, X-Ray. Female. Humans. Indoles / chemical synthesis. Indoles / chemistry. Indoles / pharmacology. Models, Molecular. Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Structure-Activity Relationship

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979395.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / (Cu(4-methylcoumarin-6,7-dioxactetate)(phenanthroline)2); 0 / Antineoplastic Agents; 0 / Indoles; 0 / Organometallic Compounds; 0 / Quinolines
  •  go-up   go-down


10. Primik MF, Mühlgassner G, Jakupec MA, Zava O, Dyson PJ, Arion VB, Keppler BK: Highly cytotoxic copper(II) complexes with modified paullone ligands. Inorg Chem; 2010 Jan 4;49(1):302-11
Hazardous Substances Data Bank. COPPER, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The new ligands (HL(2) and HL(3)) and the complexes 1-5 were characterized by (1)H and (13)C NMR, IR and electronic absorption spectroscopy, ESI mass spectrometry, and X-ray crystallography.
  • Two ligands, HL(1) and HL(2), and complexes 1-4 were tested for cytotoxicity in three human cancer cell lines, namely, CH1 (ovarian carcinoma), A549 (non-small cell lung cancer), and SW480 (colon carcinoma).
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Cell Survival / drug effects. Copper / chemistry. Copper / pharmacology. Organometallic Compounds / chemistry
  • [MeSH-minor] Benzazepines / chemistry. Carcinoma / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Cell Line, Tumor. Colonic Neoplasms / drug therapy. Female. Humans. Lung Neoplasms / drug therapy. Molecular Structure. Ovarian Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968251.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzazepines; 0 / Organometallic Compounds; 0 / paullone; 789U1901C5 / Copper
  •  go-up   go-down


11. Beauparlant P, Bédard D, Bernier C, Chan H, Gilbert K, Goulet D, Gratton MO, Lavoie M, Roulston A, Turcotte E, Watson M: Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs; 2009 Jun;20(5):346-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To translate the discovery of GMX1778 mechanism of action into optimal clinical use of its intravenously administered prodrug, GMX1777, the efficacy of GMX1777 was evaluated in xenograft models and the pharmacokinetic profile of GMX1778 and its effect on nicotinamide adenine dinucleotide cellular levels was measured by liquid chromatography/mass spectrometry.
  • Consistent with the requirement for a prolonged exposure for cytotoxicity in vitro, a dose of 75 mg/kg of GMX1777 administered as two bolus intravenous injections in 1 day were not effective at reducing the growth of multiple myeloma (IM-9) tumors, whereas the same dose of GMX1777 administered over a 24 h intravenous infusion caused tumor regression in the IM-9 model, a small-cell lung cancer (SHP-77) model, and a colon carcinoma (HCT-116) model.
  • A 72 h continuous intravenous infusion of GMX1777 was also effective in the IM-9 model, but was associated with a smaller therapeutic index.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytokines / antagonists & inhibitors. Guanidines / therapeutic use. Neoplasm Proteins / antagonists & inhibitors. Nicotinamide Phosphoribosyltransferase / antagonists & inhibitors. Prodrugs / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Animals. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / pathology. Cell Line, Tumor / transplantation. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Cyanides / administration & dosage. Cyanides / pharmacology. Cyanides / therapeutic use. Drug Screening Assays, Antitumor. Female. Humans. Infusions, Intravenous. Injections, Intravenous. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Mice. Mice, Inbred BALB C. Mice, Nude. Mice, SCID. Multiple Myeloma / drug therapy. Multiple Myeloma / pathology. NAD / metabolism. Niacin / metabolism. Niacinamide / metabolism. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. NICOTINIC ACID .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369827.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxycarbonyloxymethyl)-4-(N'-cyano-N''-(6-(4-chlorophenoxy)hexyl)-N-guanidino)pyridinium; 0 / Antineoplastic Agents; 0 / Cyanides; 0 / Cytokines; 0 / Guanidines; 0 / N-(6-chlorophenoxyhexyl)-N''-cyano-N''-4-pyridylguanidine; 0 / Neoplasm Proteins; 0 / Prodrugs; 0U46U6E8UK / NAD; 25X51I8RD4 / Niacinamide; 2679MF687A / Niacin; EC 2.4.2.12 / Nicotinamide Phosphoribosyltransferase; EC 2.4.2.12 / nicotinamide phosphoribosyltransferase, human
  •  go-up   go-down


12. Nasu K, Umekita N, Noda K, Tanaka S, Maeshiro T, Miyamoto S, Inoue S, Arai K: [A case of recurrent colon cancer patient who gained a long-term survival by repeated and aggressive surgical resection]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2150-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent colon cancer patient who gained a long-term survival by repeated and aggressive surgical resection].
  • We performed right hemicolectomy with liver S7 partial excision (a postoperative diagnosis of the hepatic lesion, adenoma) for ascending colon carcinoma of type 2 with hepatic metastasis.
  • Postoperative diagnosis was ss, n2, ly2, v2, Stage IIIb, based on the Japanese classification of colon cancer.
  • Twelve months after the first operation, she was developed intestinal atresia by an abdominal wall recurrence, and we performed the operation of abdominal wall mass resection with a partial resection of small bowel.
  • Afterwards she developed a recurrence three times in the abdominal wall or intra-abdominal lymph nodes during the next 1 year and six months, and we performed a local excision each time.
  • The pathological findings in reoperations were all metastasis from ascending colon carcinoma of primary operation.
  • After the final operation, we did not perform chemotherapy because the patient wished not to have it.
  • Recently, the therapy for recurrent colon cancer has been shifted to more effective chemotherapy such as FOLFOX or FOLFIRI regimen, and a surgical resection is becoming rare.
  • However, we experienced a case of recurrent colon cancer treated with four aggressive surgical resections that was beneficial for a long-term survival.
  • [MeSH-major] Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymphatic Metastasis. Middle Aged. Positron-Emission Tomography. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106553.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Plewa MJ, Berhow MA, Vaughn SF, Woods EJ, Rundell M, Naschansky K, Bartolini S, Wagner ED: Isolating antigenotoxic components and cancer cell growth suppressors from agricultural by-products. Mutat Res; 2001 Sep 1;480-481:109-20
Hazardous Substances Data Bank. GENISTEIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Commercial processing wastes or by-products of crops were found to be sources of antimutagens and human tumor cell growth suppressors.
  • We developed a microplate method to measure genomic DNA damage in Chinese hamster ovary cells with a modified single cell gel electrophoresis (SCGE) assay.
  • This allowed us to measure the repression of 2-acetoxyacetylaminofluorene (2AAAF)-induced DNA damage by very small amounts of complex mixtures, fractions or individual chemicals isolated from agricultural by-products.
  • We developed a microplate assay to measure the suppression of the growth rate of human cancer cells in which the cytostatic/cytotoxic status at each concentration of the test sample was quantitatively determined.
  • Genistein, genistin, daidzein and daidzin isolated from soybean fraction PCC70 expressed a wide range of growth suppression of HT-29 human colon cancer cells.
  • Compounds were purified from biologically active fractions and the structure of individual chemicals was determined with analytical HPLC and LC-mass spectroscopy (LC-MS).
  • [MeSH-major] Antimutagenic Agents / isolation & purification. Antimutagenic Agents / pharmacology. Antineoplastic Agents / isolation & purification. Antineoplastic Agents / pharmacology. Colonic Neoplasms / drug therapy. Plant Extracts / isolation & purification. Plant Extracts / pharmacology
  • [MeSH-minor] Animals. CHO Cells. Cell Division / drug effects. Chemical Fractionation. Chromatography, High Pressure Liquid. Cricetinae. DNA Damage / drug effects. Drug Screening Assays, Antitumor. Genistein / isolation & purification. Genistein / pharmacology. HT29 Cells. Humans. Isoflavones / isolation & purification. Isoflavones / pharmacology. Mass Spectrometry. Mutagenicity Tests. Soybeans / chemistry. Zea mays / chemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11506804.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimutagenic Agents; 0 / Antineoplastic Agents; 0 / Isoflavones; 0 / Plant Extracts; 1POG3SCN5T / genistin; 4R2X91A5M5 / daidzin; 6287WC5J2L / daidzein; DH2M523P0H / Genistein
  •  go-up   go-down


14. Chinot OL: [Cerebral metastases]. Rev Prat; 2006 Oct 31;56(16):1799-804
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Improvement of diagnosis techniques and cancer treatment efficacy explain in part the increasing incidence of brain metastasis, observed in 20 to 30 % of cancer patients.
  • New techniques of MRI improve its sensibility and guide therapeutic decision, in conjunction with prognostic factors including age, Karnovsky performance score and control of the general disease.
  • Surgical excision is mainly indicated for single metastasis in none functional area, or in case of mass effect, while radiosurgery represents an alternative non invasive technique, particularly for single small lesions.
  • In other cases, whole brain radiation therapy remains the treatment of choice for brain metastasis, while no clear data support it use complementary to surgery.
  • Chemotherapy has no proven efficacy as part of first line treatment of patients with brain metastasis and still warren further research.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy
  • [MeSH-minor] Administration, Oral. Adrenal Cortex Hormones / administration & dosage. Adrenal Cortex Hormones / therapeutic use. Age Factors. Aged. Breast Neoplasms. Colonic Neoplasms. Combined Modality Therapy. Humans. Karnofsky Performance Status. Kidney Neoplasms. Lung Neoplasms. Lymphoma / diagnosis. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Middle Aged. Neoplasm Recurrence, Local. Positron-Emission Tomography. Prognosis. Radiosurgery. Research

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315506.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  • [Number-of-references] 13
  •  go-up   go-down


15. Garza-Sánchez J, Hernández-Ramírez DA, Rocha-Ramírez JL, Rojas-Illanes M, Parrado-Montaño W, Cancino-López JA, Dorantes-Díaz DE, Jonguitud-Muro LA: [Non Hodgkin lymphoma of the sigmoid colon: case report]. Rev Gastroenterol Mex; 2009 Apr-Jun;74(2):127-31
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin lymphoma of the sigmoid colon: case report].
  • [Transliterated title] Linfoma no Hodgkin de sigmoides: reporte de un caso.
  • Colon is infrequently involved as a primary location, accounting for 4% of all extranodal NHL and far less than 1% of all colonic malignancies.
  • Colonic NHL differs significantly in terms of presentation, therapy and outcome relative to other more common gastrointestinal sites, like stomach or small bowel.
  • Therapy usually involves resection of the affected colon and regional lymph nodes followed by adjuvant chemotherapy or/and radiotherapy.
  • We present a 59 years old man with weight loss,abdominal pain, palpable mass and intestinal obstruction.
  • Systemic adjuvant chemotherapy and abdominal radiation were administered.
  • After a 6 month follow-up from initial procedure he is now asymptomatic with Karnofsky of 90.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666296.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


16. Chen F, Rezavi R, Wang CC, Harrison LE: Proteasome inhibition potentiates the cytotoxic effects of hyperthermia in HT-29 colon cancer cells through inhibition of heat shock protein 27. Oncology; 2007;73(1-2):98-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteasome inhibition potentiates the cytotoxic effects of hyperthermia in HT-29 colon cancer cells through inhibition of heat shock protein 27.
  • BACKGROUND: The purpose of this study was to investigate whether proteasome inhibition acts as a thermal sensitizing agent to induce tumor cell death in a colon cancer cell line.
  • METHODS: HT-29 colon cancer cells were exposed to hyperthermia (43 degrees C) in the presence of proteasome inhibition for 1 h.
  • Viable cell mass and apoptosis were measured by MTT and annexin V staining, respectively.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis. Colonic Neoplasms / metabolism. Colonic Neoplasms / therapy. Enzyme Inhibitors / pharmacology. Heat-Shock Proteins / antagonists & inhibitors. Hyperthermia, Induced. Proteasome Inhibitors
  • [MeSH-minor] Blotting, Western. Butadienes / pharmacology. Cell Proliferation / drug effects. Cell Survival / drug effects. Cysteine Proteinase Inhibitors / pharmacology. Dose-Response Relationship, Drug. Drug Synergism. Electrophoresis, Polyacrylamide Gel. HT29 Cells. Humans. Leupeptins / pharmacology. Nitriles / pharmacology. Protease Inhibitors / pharmacology. RNA, Small Interfering / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18337621.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Butadienes; 0 / Cysteine Proteinase Inhibitors; 0 / Enzyme Inhibitors; 0 / Heat-Shock Proteins; 0 / Leupeptins; 0 / Nitriles; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / RNA, Small Interfering; 0 / U 0126; 0 / carbobenzoxy-leucyl-leucyl-norvalinal; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde
  •  go-up   go-down


17. Chatelain D, Maes C, Yzet T, Brevet M, Bounicaud D, Plachot JP, Verhaeghe P: [Primary hepatic lymphoma of MALT-type: a tumor that can simulate a liver metastasis]. Ann Chir; 2006 Feb;131(2):121-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary hepatic lymphoma of MALT-type: a tumor that can simulate a liver metastasis].
  • [Transliterated title] Le lymphome primitif hépatique de type MALT: une tumeur rare pouvant simuler une métastase hépatique.
  • We report a case of a 72 year-old woman with a past history of colonic adenocarcinoma who presented primary hepatic lymphoma of MALT-type.
  • The patient had been operated on 3 years before for colonic adenocarcinoma, pT3N0, revealed by a bowel obstructive syndrome.
  • She had been treated by chemotherapy for 6 months.
  • During the follow-up, the computed tomography-scan (CT-scan) revealed the presence of a not well-demarcated mass in segment III of the liver, measuring 4 cm in diameter.
  • The tumor was hypodense and was not enhanced on dynamic study.
  • The mass was already present on the initial CT-scan.
  • Left lobectomy was performed with the diagnosis of liver metastasis of the colonic adenocarcinoma.
  • Surgical specimen showed a tumor composed of a dense infiltrate of small lymphocytes positive for B-cell markers on immunohistochemistry.
  • The tumor contained reactive lymphoid follicles and there were numerous lympho-epithelial biliary lesions.
  • Primary hepatic lymphoma of MALT-type is a low-grade B cell lymphoma.
  • This tumor has a good prognosis; it is usually limited to the liver and surgical resection cures the patient in most cases.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16246295.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 18
  •  go-up   go-down


18. Mandir N, Goodlad RA: Conjugated linoleic acids differentially alter polyp number and diameter in the Apc(min/+) mouse model of intestinal cancer. Cell Prolif; 2008 Apr;41(2):279-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CLAs have also been linked to altered rates of cell renewal and cell proliferation so this was also studied, as was a further means of increasing tissue mass, namely crypt fission.
  • RESULTS: The stomach and small intestine were significantly heavier in the t10c12, and in the mixture-treated groups (P < 0.001).
  • Crypt fission was increased in the middle small intestine by the t10c12 diet while colonic weight was reduced by c9t11 provision and crypts were 20% shorter.
  • The t10c12 and the mixture significantly reduced polyp number in the proximal small intestine but they increased polyp diameter in the middle and distal small intestine, to an extent that the polyp burden was significantly increased at these sites.
  • All CLAs significantly reduced polyp number in the colon, but the mixture significantly increased polyp diameter in the colon.
  • The naturally occurring isomer, c9t11 decreased colonic polyp number and did not increase diameter, suggesting that this natural isomer is the most likely to be protective.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Intestinal Neoplasms / prevention & control. Intestinal Polyps / drug therapy. Linoleic Acids, Conjugated / administration & dosage
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Chemoprevention. Dietary Supplements. Disease Models, Animal. Female. Isomerism. Male. Mice. Mice, Inbred C57BL. Mitosis / drug effects. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336472.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Linoleic Acids, Conjugated; 0 / beta Catenin; 0 / cis-9, trans-11-conjugated linoleic acid; 0 / trans-10,cis-12-conjugated linoleic acid
  •  go-up   go-down


19. Kim JH, Jung CH, Jang BH, Go HY, Park JH, Choi YK, Hong SI, Shin YC, Ko SG: Selective cytotoxic effects on human cancer cell lines of phenolic-rich ethyl-acetate fraction from Rhus verniciflua Stokes. Am J Chin Med; 2009;37(3):609-20
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liquid chromatography-mass spectrometry (LC-MS) analysis showed that the PPEF contained gallic acid, protocatechuic acid, fisetin, sulfuretin, butein and 8 unknown compounds.
  • There were only small amounts of flavonoids: fisetin, sulfuretin and butein.
  • The results showed that PPEF induces apoptosis only in gastric and breast cancer cell lines, but not in lung, colon or liver cancer cell lines.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Drugs, Chinese Herbal / pharmacology. Rhus / chemistry. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Acetates. Apoptosis / drug effects. Carcinoma, Hepatocellular. Cell Division / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Colonic Neoplasms. Ethanol. Female. Flavonoids / analysis. Flavonoids / pharmacology. Humans. Liver Neoplasms. Lung Neoplasms. Phenol. Solvents

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. PHENOL .
  • Hazardous Substances Data Bank. SODIUM PHENOLATE .
  • Hazardous Substances Data Bank. ETHYL ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606519.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Acetates; 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal; 0 / Flavonoids; 0 / Solvents; 339NCG44TV / Phenol; 3K9958V90M / Ethanol; 76845O8NMZ / ethyl acetate
  •  go-up   go-down


20. Sugiura T, Noguchi Y, Sakurai K, Hattori C: Protein phosphatase 1H, overexpressed in colon adenocarcinoma, is associated with CSE1L. Cancer Biol Ther; 2008 Feb;7(2):285-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein phosphatase 1H, overexpressed in colon adenocarcinoma, is associated with CSE1L.
  • In search for a new anticancer drug target, we explored genes involved in colon adenocarcinoma development through dysregulation of a signal transduction pathway.
  • By using the gene expression profile database, we found protein phosphatase 1H (PPM1H), belonging to the protein phosphatase 2C (PP2C) family, upregulated in colon adenocarcinomas compared with normal colon tissues.
  • RT-PCR analysis verified the elevated level of PPM1H expression in colon cancer cell lines relative to a normal colon cell line.
  • PPM1H encodes a protein with a molecular mass of approximately 50 kDa that resides in the cytoplasm.
  • Co-immunoprecipitation coupled with mass spectrometry analysis identified CSE1L, a proliferation and apoptosis-related protein, as a PPM1H-interacting protein.
  • Native, but not inactive, PPM1H expressed in HeLa cells increased the mobility of CSE1L on SDS gels and a similar mobility shift was observed for purified CSE1L after treatment with PPM1H in vitro, supporting the notion that CSE1L is a substrate of PPM1H.
  • Additionally, knockdown of PPM1H expression with small interfering RNAs suppressed the growth of MCF-7 cells weakly but consistently.
  • PPM1H controls cell cycle and proliferation of cancer cells potentially through dephosphorylation of CSE1L and might be a new target of anticancer drugs.
  • [MeSH-major] Adenocarcinoma / metabolism. Cellular Apoptosis Susceptibility Protein / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Phosphoprotein Phosphatases / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2008 Feb;7(2):293-4 [18623903.001]
  • (PMID = 18059182.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cellular Apoptosis Susceptibility Protein; EC 3.1.3.16 / PPM1H protein, human; EC 3.1.3.16 / Phosphoprotein Phosphatases; EC 3.1.3.16 / protein phosphatase 2C
  •  go-up   go-down


21. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD: Current status of gastrointestinal carcinoids. Gastroenterology; 2005 May;128(6):1717-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoids are classified based on organ site and cell of origin and occur most frequently in the GI (67%) where they are most common in small intestine (25%), appendix (12%), and rectum (14%).
  • Local manifestations--mass, bleeding, obstruction, or perforation--reflect invasion or tumor-induced fibrosis and often result in incidental detection at emergency surgery.
  • Biochemical diagnosis is established by elevation of plasma chromogranin A (CgA), serotonin, or urinary 5-hydroxyindoleacetic acid (5-HIAA), while topographic localization is by Octreoscan, computerized axial tomography (CAT) scan, or endoscopy/ultrasound.
  • Primary therapy is surgical excision to avert local manifestations and decrease hormone secretion.
  • Chemotherapy and radiotherapy have minimal efficacy and substantially decrease quality of life.
  • Local endoscopic excision for gastric (type I and II) and rectal carcinoids may be adequate.
  • Somatostatin analogues provide the most effective symptomatic therapy, although interferon has some utility.
  • Overall 5-year survival for carcinoids of the appendix is 98%, gastric (types I/II) is 81%, rectum is 87%, small intestinal is 60%, colonic carcinoids is 62%, and gastric type III/IV is 33%.
  • [MeSH-major] Carcinoid Tumor / pathology. Carcinoid Tumor / therapy. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / therapy


22. Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, Jeong JW, Kim YJ: Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res; 2010 Mar;48(2):178-84
Hazardous Substances Data Bank. MELATONIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia.
  • Angiogenesis is an important mediator of tumor progression.
  • Sustained expansion of a tumor mass requires new blood vessel formation to provide rapidly proliferating tumor cells with an adequate supply of oxygen and nutrients.
  • HIF-1alpha is stabilized by hypoxia-induced reactive oxygen species (ROS) and enhances the expression of several types of hypoxic genes, including that of the angiogenic activator known as vascular endothelial cell growth factor (VEGF).
  • In this study, we found that melatonin, a small lipophilic molecule secreted primarily by the pineal gland, destabilizes hypoxia-induced HIF-1alpha protein levels in the HCT116 human colon cancer cell line.
  • These findings suggest that melatonin could play a pivotal role in tumor suppression via inhibition of HIF-1-mediated angiogenesis.
  • [MeSH-major] Cell Hypoxia / drug effects. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Melatonin / pharmacology. Neovascularization, Pathologic / drug therapy
  • [MeSH-minor] Antioxidants / pharmacology. Cells, Cultured. Colonic Neoplasms / pathology. Culture Media, Conditioned / pharmacology. Humans. Tumor Cells, Cultured. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449875.001).
  • [ISSN] 1600-079X
  • [Journal-full-title] Journal of pineal research
  • [ISO-abbreviation] J. Pineal Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Culture Media, Conditioned; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Vascular Endothelial Growth Factor A; JL5DK93RCL / Melatonin
  •  go-up   go-down






Advertisement